CALR genotype-associated viability responses
Cell-based study · Murine Ba/F3-MPL CALR WT, del79/WT and del37/del37 cells; human UT-7/TPO CALR WT and heterozygous mutant cells (del58/WT in Figure 2D). [1]
At 72 hours, hematoxylin reduced CellTiter-Glo viability with lower reported IC50 values in mutant-CALR models than WT comparators. The separation was smaller in the human UT-7/TPO model. WT and mutant monocultures had different cytokine conditions, which limits interpretation of genotype selectivity from these dose-response experiments alone.
| Endpoint | Reported result | Reference |
|---|---|---|
| 72-hour CellTiter-Glo viability in CALR-mutant Ba/F3-MPL cells | IC50 2.90 ± 0.67 μM | [1] |
| 72-hour CellTiter-Glo viability in CALR-WT Ba/F3-MPL cells | IC50 11.18 ± 2.87 μM | [1] |
| 72-hour CellTiter-Glo viability in CALR-mutant UT-7/TPO cells | IC50 16.01 ± 2.27 μM | [1] |
| 72-hour CellTiter-Glo viability in CALR-WT UT-7/TPO cells | IC50 33.61 ± 3.28 μM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Hematoxylin concentration-response series; the full list of individual tested concentrations is not tabulated in the acquired main text.
- Exposure duration
- 72 hours
- Method
- CellTiter-Glo luminescent cell viability assay. WT cells received 1% TPO-conditioned medium; CALR-mutant cells were assayed without cytokine.
- Vehicle
- DMSO; all drug-treatment groups contained equal amounts of DMSO (Figure 2C–D caption).
- Reported limits
- Exact DMSO percentage and full concentration-point list were not established from the acquired main text. Figure 2C–D reports n = 6; the experimental unit and the aggregation used for the reported mutant IC50 are not explicit. ± values are retained as reported; the figure describes mean ± SD, without separately defining uncertainty for fitted IC50 values.
Methods and source locations
Compound reported in the paper: Hematoxylin; Compound label in the paper: Hematoxylin
Evidence concerns the hematoxylin tested by Jia et al.; it does not validate an Adooq lot, purity or stereochemical composition.
Methods: Cell viability assay; Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C–D and caption
72-hour CellTiter-Glo viability in CALR-mutant Ba/F3-MPL cells: Luminescent cell viability assay; reported mutant IC50 summary. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C
72-hour CellTiter-Glo viability in CALR-WT Ba/F3-MPL cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2C
72-hour CellTiter-Glo viability in CALR-mutant UT-7/TPO cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2D
72-hour CellTiter-Glo viability in CALR-WT UT-7/TPO cells: Luminescent cell viability assay. — Results: Identification of compounds that selectively reduce the viability of CALR-mutant cells; Figure 2D